Want to take quizzes and track your credits?
In the December 1, 2020, issue of JAMA, Self et al1 reported a randomized clinical trial that evaluated whether treatment with hydroxychloroquine improved clinical outcomes of adults hospitalized with COVID-19 compared with placebo. The primary outcome was the patient’s clinical status 14 days after randomization, assessed with an ordinal 7-category scale ranging from worst (“death”) to the best (“discharged from the hospital and able to perform normal activities”). The term “ordinal” is applied to an outcome measure for which its mutually exclusive categories can be ordered by their clinical preference. The primary outcome was analyzed with a multivariable ordinal logistic regression model, which is a regression model for an ordinal dependent variable. The authors found that there was not a statistically significant difference between the hydroxychloroquine and placebo groups in clinical status 14 days after randomization.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Benjamin French, PhD, Department of Biostatistics, Vanderbilt University Medical Center, 2525 West End Ave, Ste 1100, Nashville, TN 37203 (email@example.com).
Published Online: August 4, 2022. doi:10.1001/jama.2022.12104
Conflict of Interest Disclosures: None reported.
You currently have no searches saved.
You currently have no courses saved.